Madhavi Netralaya Institute

Research and Innovation

Peer-reviewed ophthalmology scholarship from our consultants — bringing evidence in retina therapeutics, biosimilars, and anti-VEGF care into clinical practice at Ara, Bihar.

39DOI publications
2022–2026Publication years
RetinaPrimary focus

Madhavi Netralaya is a tertiary eye hospital — and an institute that treats research as part of patient care. Our consultants publish in journals such as Eye, Ophthalmology, JAMA Ophthalmology, and Expert Opinion on Biological Therapy, collaborating with national and international retina groups on biosimilars, faricimab, port delivery systems, and real-world anti-VEGF practice.

The list below is our curated DOI catalogue of published work. Each entry links to the DOI resolver so you can read the original paper. For live PubMed results under our institutional affiliation, use the PubMed link at the bottom of this page.

Published DOI list

39 peer-reviewed publications with DOIs — newest first.

  1. Real-world effectiveness and safety of ranibizumab biosimilar FYB-201 in Saudi Arabia (Ravegza) and Jordan (Uptera): a middle eastern extension of the FORCE study

    Sharma A., Abdelshafy Tabl A., Rihani H., Tabl M., Shebl A., Abousaif W., et al.

    2026 · Eyedoi:10.1038/s41433-026-04537-7

  2. Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study

    Sharma A., Khanani A., Eichenbaum D., Boyer D., Shaer A., Ortiz T., et al.

    2026 · Eyedoi:10.1038/s41433-026-04327-1

  3. Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience—ROSE Korea Study

    Song J., Park U., Lee C., Cho J., Kim J., Baek S., et al.

    2026 · Scientific Reportsdoi:10.1038/s41598-025-34325-4

  4. FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings – FORCE study

    Sharma A., Nicholson L., Vazquez-Alfageme C., Sivagnanavel V., Fausto R., Soare M., et al.

    2025 · Eyedoi:10.1038/s41433-025-04030-7

  5. Aflibercept 2 mg biosimilar (Tyalia) - real-world experience from IRAN (ATRIA study)

    Avadzadeh S., Sharma A., Parvaresh M., Ghasemi Falavarjani K., , Kuppermann B., et al.

    2025 · Eyedoi:10.1038/s41433-025-03813-2

  6. Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study)

    Ueda-Consolvo T., Ishida M., Nakamura T., Yanagisawa S., Tsuboi K., Wakabayashi T., et al.

    2024 · Eyedoi:10.1038/s41433-024-03220-z

  7. Aflibercept vs ranibizumab biosimilars: manufacturing differences that might matter in the long run

    Sharma A., Bandello F., Bandyopadhyay S., Kumar N., Parachuri N.

    2026 · Eyedoi:10.1038/s41433-025-04167-5

  8. Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study

    Sharma A., Holz F., Kumar N., Sarraf D., Ayachit S., Mishra C., et al.

    2025 · Journal of VitreoRetinal Diseasesdoi:10.1177/24741264251322213

  9. Aflibercept 2 mg biosimilars—will they lead the Anti-VEGF biosimilar world globally

    Sharma A., Woo S., Lee C., Kumar N., Parachuri N., Bandello F., et al.

    2025 · Eyedoi:10.1038/s41433-025-03732-2

  10. Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI)

    Sharma A., Kaiser P., Tadayoni R., Holz F., Nicholson L., Vazquez-Alfageme C., et al.

    2024 · Eyedoi:10.1038/s41433-024-03284-x

  11. Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study

    Sharma A., Wakabayashi T., Regillo C., Cheung C., Loewenstein A., Zur D., et al.

    2024 · Eyedoi:10.1038/s41433-024-03275-y

  12. Global experience of faricimab in clinical settings - a review

    Sharma A., Kumar N., Parachuri N., Loewenstein A., Bandello F., Kuppermann B.

    2024 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2024.2336087

  13. Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs

    Sharma A., Kumar N., Parachuri N., Bandello F., Loewenstein A., Kuppermann B.

    2024 · Eyedoi:10.1038/s41433-024-03001-8

  14. Knowledge, attitude, and practice patterns of Indian ophthalmologists regarding medicolegal issues

    Agrawal D., Heda A., Ghosh S., Kalia S., Bhatia K., Kumar N., et al.

    2023 · Indian Journal of Ophthalmologydoi:10.4103/IJO.IJO_1084_23

  15. Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases

    Sharma A., Loewenstein A., Parachuri N., Kumar N., Kuppermann B.

    2023 · Journal of VitreoRetinal Diseasesdoi:10.1177/24741264231202080

  16. Aflibercept biosimilars – update on the development progress

    Sharma A., Loewenstein A., Kumar N., Parachuri N., Bandello F., Kuppermann B.

    2024 · Eyedoi:10.1038/s41433-023-02813-4

  17. Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge–

    Sharma A., Loewenstein A., Parachuri N., Kumar N., Rasal A., Bandello F., et al.

    2024 · Eyedoi:10.1038/s41433-023-02698-3

  18. Re: Zhang et al.: The biosimilar paradox: how anti-VEGF biosimilars will increase patient and overall healthcare costs (Ophthalmology. 2023;130:966-973)

    Sharma A., Kumar N., Parachuri N., Bandello F.

    2023 · Ophthalmologydoi:10.1016/j.ophtha.2023.07.019

  19. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia

    Sharma A., Kumar N., Parachuri N., Loewenstein A., Bandello F., Kuppermann B.

    2023 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2023.2239706

  20. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)

    Sharma A., Holz F., Regillo C., Freund K., Sarraf D., Khanani A., et al.

    2023 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2023.2176218

  21. Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists

    Sharma A., Khanani A., Parachuri N., Kumar N., Bandello F., Kuppermann B.

    2023 · International Journal of Retina and Vitreousdoi:10.1186/s40942-023-00446-z

  22. Commentary: The tinsels and tassels of smartphone ophthalmic photography

    Kumar N., Sharma A.

    2023 · Indian Journal of Ophthalmologydoi:10.4103/ijo.IJO_2223_22

  23. Biosimilar Ranibizumab and Innovator Ranibizumab—Immunogenicity Assessment and Its Impact on Safety and Efficacy

    Sharma A., Kumar N., Kuppermann B.

    2023 · JAMA Ophthalmologydoi:10.1001/jamaophthalmol.2022.5543

  24. Immunogenicity: Clouding the Future of Intravitreal Therapy

    Sharma A., Kumar N., Parachuri N., Bandello F., Kuppermann B.

    2023 · Ocular Immunology and Inflammationdoi:10.1080/09273948.2022.2139273

  25. Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians–

    Sharma A., Kumar N., Parachuri N., Regillo C., Bandello F., Kuppermann B.

    2023 · Eyedoi:10.1038/s41433-022-02287-w

  26. Approved biosimilar ranibizumab—a global update

    Sharma A., Kondo M., Iwahashi C., Parachuri N., Kumar N., Bandello F., et al.

    2023 · Eyedoi:10.1038/s41433-022-02246-5

  27. Biosimilar anti-VEGF—Yardsticks to ensure biosimilarity

    Sharma A., Parachuri N., Kumar N., Bandello F., Kuppermann B.

    2023 · Eyedoi:10.1038/s41433-022-02177-1

  28. Brolucizumab in polypoidal choroidal vasculopathy

    Sharma A., Parachuri N., Kumar N., Kuppermann B., Loewenstein A., Bandello F.

    2022 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2022.2094239

  29. Supplemental nutrition for retinal health: Evidence based analysis of commercial preparations in India

    Sharma A., Kumar N., Parachuri N., Kuppermann B., Bandello F.

    2022 · Indian Journal of Ophthalmologydoi:10.4103/ijo.IJO_3101_21

  30. Fear of safety compromise with biosimilar anti-VEGF—perception or truth

    Sharma A., Kumar N., Parachuri N., et al.

    2022 · Eyedoi:10.1038/s41433-022-02117-z

  31. The port delivery system with ranibizumab: understanding nuances for clinical use in the real world

    Sharma A., Parachuri N., Kumar N., Kuppermann B., Bandello F., Regillo C.

    2022 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2022.2078162

  32. Ranizurel safety evaluation in real-world -(RaSER) study

    Sharma A., Arunaprakash J., Das A., Nayaka A., Kumar N., Parachuri N., et al.

    2022 · American Journal of Ophthalmology Case Reportsdoi:10.1016/j.ajoc.2022.101358

  33. Retina: a unique subspecialty in the biosimilar landscape

    Sharma A., Kumar N., Parachuri N., Regillo C., Bandello F., Kuppermann B.

    2022 · Eyedoi:10.1038/s41433-022-01984-w

  34. On label bevacizumab for retina: where it stands

    Sharma A., Kumar N., Parachuri N., Loewenstein A., Bandello F., Kuppermann B.

    2022 · Eyedoi:10.1038/s41433-021-01909-z

  35. Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk

    Sharma A., Kumar N., Parachuri N., Sahyoun J., Kuppermann B., Bandello F.

    2022 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2022.2028772

  36. Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials

    Sharma A., Kumar N., Parachuri N., et al.

    2022 · Eyedoi:10.1038/s41433-021-01831-4

  37. The Port Delivery System with ranibizumab—journey of mitigating vitreous hemorrhage

    Sharma A., Parachuri N., Kumar N., Kuppermann B., Bandello F.

    2022 · Eyedoi:10.1038/s41433-021-01830-5

  38. Brolucizumab—early experience with early extended interval regime in chronic centre involved diabetic macular oedema

    Chakraborty D., Mondal S., Parachuri N., Kumar N., Sharma A.

    2022 · Eyedoi:10.1038/s41433-021-01816-3

  39. Semaglutide and the risk of diabetic retinopathy—current perspective

    Sharma A., Parachuri N., Kumar N., Saboo B., Tripathi H., Kuppermann B., et al.

    2022 · Eyedoi:10.1038/s41433-021-01741-5

Explore further

Browse affiliation-indexed PubMed results, meet the surgeons behind this work, or book a consultation at Madhavi Netralaya.

View on PubMed → Book appointment Dr. Nilesh Kumar